Trending menu:
Comment
-
14 February 2020
Experts divided on Avrobio’s phase two gene therapy for Fabry disease
While Avrobio’s available AVR-RD-01 data in Fabry disease is overall too limited to forecast success prospects in the 12-patient phase two trial, experts were divided on whether initial phase two data...
-
14 February 2020
Ovid is considering expanding Phase III trial size of gaboxadol in Angelman syndrome
Ovid Therapeutics is considering potentially increasing the size of its Phase III gaboxadol trial in Angelman syndrome (AS) given global interest and other considerations for the trial, said a spokesperson....
-
12 February 2020
BMS positioned to lead in the multiple myeloma market
Chimeric antigen receptor T-cell (CAR-T) therapies have become standard of care for certain haematological malignancies due to their unprecedented specificity to the patients’ individual immune system. Despite the theoretical advantages,...
-
12 February 2020
Failure of DIAN-TU drug trial for Alzheimer’s disease
Eli Lilly and F. Hoffman-La Roche announced the failure of the clinical trial named DIAN-TU, which was testing two monoclonal antibody (mAb) drugs for Alzheimer’s disease (AD), Roche’s gantenerumab and...
-
7 February 2020
Phase IV trial results show Eylea dosing schedule improvement is possible
Bayer's recently released results from the trial have shown that there can be greater flexibility in the treatment regimen for patients with macular degeneration using Eylea.
-
7 February 2020
Future of Merck KGaA/Pfizer’s Bavencio at risk despite bladder trial success
The recent success of Pfizer and Merck KGaA’s Phase III JAVELIN Bladder 100 confirmatory study investigating Bavencio (avelumab) with best supportive care as the first-line maintenance treatment for patients with...
-
5 February 2020
Enthusiasm for coronavirus treatments offers hope but rushed trials could be dangerous
A number of companies, ranging from small biotechs with no marketed products, to larger players with notable infectious disease experience, such as Gilead and Johnson & Johnson, have thrown their...
-
5 February 2020
Clinical investigations in Coronaviridae infections
According to the World Health Organization, Coronaviridae or 'coronaviruses' are a large family of viruses that can cause illnesses ranging from the common cold to respiratory symptoms, fever, cough, shortness...
-
4 February 2020
Immunotherapies could help to treat acute myeloid leukemia
Despite immunotherapy combinations revolutionising the treatment of most cancer indications, the acute myeloid leukemia (AML) market has lagged behind. However, with a large number of new agents that target novel...
-
3 February 2020
Non-industry-sponsored clinical trials landscape: 2019
A clinical trial can be sponsored by an industry (company) or non-industry (government, individual/investigator-initiated, or institution). Figure one: Non-industry-sponsored clinical trials by year. Credit: GlobalData. When looking at non-industry-sponsored clinical...